Rigel Pharmaceuticals Inc... (RIGL)

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. R...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfo...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.

The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...